Replimune Group, Inc.
REPL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001737953
In the last 90 days, Replimune Group, Inc. insiders filed 0 open-market purchases and 5 sales; 199 institutions reported holding it in 13F filings for Q2 2026, worth $1.06B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Replimune Group, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 5 filings
- 4 insiders, $1.04M in total
- Insiders trading
- 4
- Net value
- −$1.04M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Replimune Group, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Astley-Sparke Philip | Director | 1,362,414 | Aug 24, 2026 | 4 |
| Hill Emily Luisa | Chief Financial Officer | 215,852 | Aug 19, 2026 | 5 |
| Patel Sushil | Chief Executive Officer | 708,151 | Aug 12, 2026 | 5 |
| Xynos Konstantinos | Chief Medical Officer | 224,215 | Aug 12, 2026 | 5 |
| Schwendenman Andrew | Chief Accounting Officer | 99,425 | Aug 12, 2026 | 4 |
| Baker Julian | Director, 10% Owner | – | Aug 11, 2026 | 2 |
| Baker Felix | Director, 10% Owner | – | Aug 11, 2026 | 2 |
| Baker Bros. Advisors LP | Director, 10% Owner | – | Aug 11, 2026 | 2 |
| Baker Brothers Life Sciences LP | Director, 10% Owner | – | Aug 11, 2026 | 2 |
| 667, L.P. | Director, 10% Owner | – | Aug 11, 2026 | 2 |
| Baker Bros. Advisors (GP) LLC | Director, 10% Owner | – | Aug 11, 2026 | 2 |
| Sarchi Christopher | Chief Commercial Officer | 180,962 | Jun 3, 2026 | 6 |
| Slattery Joseph P | Director | – | Apr 7, 2026 | 1 |
| Pucci Paolo | Director | – | Apr 7, 2026 | 1 |
| Dhingra Kapil | Director | 0 | Apr 7, 2026 | 2 |
| Balachandran Madhavan | Director | – | Apr 7, 2026 | 1 |
| Weinand Dieter | Director | – | Apr 7, 2026 | 1 |
| Oliger Christy J. | Director | – | Apr 7, 2026 | 1 |
| Peeples-Dyer Veleka | Director | – | Apr 7, 2026 | 1 |
| Coffin Robert | Director | 1,821,872 | May 20, 2024 | 0 |
| Love Colin | Chief Operating Officer | 777,345 | May 20, 2024 | 0 |
| Levitsky Hyam | Director | – | Apr 3, 2024 | 0 |
| Esposito Pamela | Chief Business Officer | 263,436 | Sep 13, 2023 | 0 |
| Lewis Tanya | Chief Dev. Op. Officer | 135,293 | Jun 15, 2023 | 0 |
| Franchi Jean M. | Chief Financial Officer | 128,748 | May 18, 2023 | 0 |
| Slootweg Hugo Alexander | Director | – | Apr 4, 2023 | 0 |
| Rhodes Jason P | Director | – | Apr 5, 2022 | 0 |
| Stampacchia Otello | 10% Owner | 4,673,380 | Mar 16, 2022 | 0 |
| Omega Fund IV, L.P. | 10% Owner | 4,673,380 | Mar 16, 2022 | 0 |
| Omega Fund IV GP, L.P. | 10% Owner | 4,673,380 | Mar 16, 2022 | 0 |
| Omega Fund IV G.P. Manager, Ltd. | 10% Owner | 4,673,380 | Mar 16, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 18, 2023 (view filing) | May 16 | 2 days | Xynos KonstantinosChief Medical Officer | SSale | −771 | $18.05 | −$13.9K | −0.6%120.0K after | |
| May 18, 2023 (view filing) | May 16 | 2 days | Esposito PamelaChief Business Officer | SSale | −5.97K | $18.05 | −$107.7K | −2.2%263.4K after | |
| May 18, 2023 (view filing) | May 16 | 2 days | Astley-Sparke PhilipChief Executive Officer | SSale | −17.9K | $18.05 | −$323.1K | −1.2%1.53M after | |
| Dec 13, 2022 (view filing) | Dec 9 | 4 days | Esposito PamelaChief Business Officer | SSale | −15.0K | $25.03 | −$375.4K | −6.1%229.4K after | |
| May 18, 2022 (view filing) | May 16 | 2 days | Love ColinChief Operating Officer | SSale | −6.32K | $14.59 | −$92.3K | −0.8%765.7K after | |
| May 18, 2022 (view filing) | May 16 | 2 days | Esposito PamelaChief Business Officer | SSale | −3.51K | $14.59 | −$51.2K | −1.5%229.4K after | |
| May 18, 2022 (view filing) | May 16 | 2 days | Franchi Jean M.Chief Financial Officer | SSale | −3.44K | $14.59 | −$50.1K | −3.5%95.1K after | |
| May 18, 2022 (view filing) | May 16 | 2 days | Lewis TanyaChief Dev. Op Officer | SSale | −5.47K | $14.59 | −$79.9K | −4.3%120.4K after | |
| May 18, 2022 (view filing) | May 16 | 2 days | Patel SushilChief Commercial Officer | SSale | −10.7K | $14.59 | −$155.9K | −7.6%130.1K after | |
| May 18, 2022 (view filing) | May 16 | 2 days | Coffin RobertPresident & Chief R&D Officer | SSale | −5.74K | $14.59 | −$83.7K | −0.3%1.80M after | |
| May 18, 2022 (view filing) | May 16 | 2 days | Astley-Sparke PhilipChief Executive Officer | SSale | −9.63K | $14.59 | −$140.5K | −0.7%1.40M after | |
| Mar 16, 2022 (view filing)9:54 PM ET | Mar 14 | 2 days | Stampacchia Otello and 3 others10% Owner | SSale | −16.5K | $15.42 | −$254.4K | −0.3%4.76M after | |
| Mar 16, 2022 (view filing)9:54 PM ET | Mar 15-16 | 1 day | Stampacchia Otello and 3 others10% Owner | SSale | −90.0K | $15.58 | −$1.40M | −1.9%4.67M after | 3 lots |
| Nov 23, 2021 (view filing)4:53 PM ET | Nov 19-22 | 4 days | Stampacchia Otello and 3 othersDirector | SSale | −45.4K | $34.58 | −$1.57M | −0.9%4.76M after | 3 lots |
| Nov 18, 2021 (view filing)6:30 PM ET | Nov 16-18 | 2 days | Stampacchia Otello and 3 othersDirector | SSale | −2.59K | $33.50 | −$86.9K | −0.1%4.81M after | 2 lotsDuplicate filing |
| Nov 18, 2021 (view filing)6:30 PM ET | Nov 16-18 | 2 days | Stampacchia Otello and 3 othersDirector | SSale | −2.59K | $33.50 | −$86.9K | −0.1%4.81M after | 2 lots |
| Nov 16, 2021 (view filing)1:29 PM ET | Nov 12-15 | 4 days | Stampacchia Otello and 3 othersDirector | SSale | −24.0K | $33.66 | −$808.4K | −0.5%4.81M after | 2 lots |
| Nov 12, 2021 (view filing)1:08 PM ET | Nov 10-11 | 2 days | Stampacchia Otello and 3 othersDirector | SSale | −18.3K | $33.61 | −$614.7K | −0.4%4.84M after | 2 lots |
| Nov 10, 2021 (view filing)12:16 PM ET | Nov 8-9 | 2 days | Stampacchia Otello and 3 othersDirector | SSale | −11.4K | $33.66 | −$382.2K | −0.2%4.85M after | 2 lots |
| Nov 8, 2021 (view filing)2:14 PM ET | Nov 4-5 | 4 days | Stampacchia Otello and 3 othersDirector | SSale | −31.0K | $33.57 | −$1.04M | −0.6%4.87M after | 2 lots |
| Oct 19, 2021 (view filing) | Oct 15-18 | 4 days | Love ColinChief Operating Officer | SSale | −30.0K | $30.06 | −$901.9K | −3.9%745.8K after | 3 lots |
| Sep 27, 2021 (view filing)8:50 PM ET | Sep 23 | 4 days | Stampacchia Otello and 3 othersDirector, 10% Owner | SSale | −12.2K | $33.58 | −$408.7K | −0.2%4.90M after | |
| Sep 20, 2021 (view filing)12:53 PM ET | Sep 16-17 | 4 days | Stampacchia Otello and 3 othersDirector, 10% Owner | SSale | −100.0K | $32.99 | −$3.30M | −2.0%4.91M after | 3 lots |
| Sep 17, 2021 (view filing) | Sep 15 | 2 days | Love ColinChief Operating Officer | SSale | −30.0K | $31.23 | −$936.9K | −3.7%775.8K after | |
| Aug 18, 2021 (view filing) | Aug 16 | 2 days | Love ColinChief Operating Officer | SSale | −30.0K | $29.93 | −$898.0K | −3.6%805.8K after | 2 lots |
| Aug 6, 2021 (view filing) | Aug 4-5 | 2 days | Esposito PamelaChief Business Officer | SSale | −30.0K | $35.08 | −$1.05M | −12.5%210.2K after | 2 lots |
| Jul 22, 2021 (view filing) | Jul 20-21 | 2 days | Esposito PamelaChief Business Officer | SSale | −17.4K | $33.14 | −$576.6K | −7.6%210.2K after | 2 lots |
| Jul 19, 2021 (view filing) | Jul 15 | 4 days | Esposito PamelaChief Business Officer | SSale | −4.60K | $33.37 | −$153.5K | −2.1%210.2K after | |
| Jul 19, 2021 (view filing) | Jan 14-19 | 186 days | Esposito PamelaChief Business Officer | SSale | −55.0K | $43.99 | −$2.42M | −23.8%176.0K after | Amended4 lots |
| Jul 16, 2021 (view filing) | Jul 15 | 1 day | Love ColinChief Operating Officer | SSale | −30.0K | $32.02 | −$960.6K | −3.5%835.8K after | |
| Jul 7, 2021 (view filing) | Jul 2 | 5 days | Coffin RobertPresident & Chief R&D Officer | SSale | −7.81K | $40.04 | −$312.7K | −0.4%1.78M after |